Successful Intravitreal Injection of Ranibizumab for Age-Related Macular Degeneration (AMD) in Young Adults: A Case Report

Basyar Adnani, Norma Hanifah Sumarta, Siti Roziah Ria Famuji, Alif Raudhah Husnul Khotimah, Putri Aulawiya Rosyida Halim, Yuliono Trika Nur Hasan, Lina Puspita Hutasoit

Abstract


Background:  Age Related Macular Degeneration (AMD) is a chronic condition that specifically affects the central retina and is widespread in developed nations. The hypothesis suggests that as the population ages, the occurrence and impact of AMD will rise due to the significant risk factor of being over 55 years old, which is most prevalent among the elderly. Bevacizumab, ranibizumab, and aflibercept have established themselves as the gold standard of therapy. Case Report:  We present the case of a middle-aged man with age-related macular degeneration (AMD) and no concomitant diseases who showed remarkable improvement after intravitreal injection with patizra (ranibizumab). A 44-year-old Asian man was administered Patizra injections for three consecutive months after developing age-related macular degeneration. After intravitreal injection of ranibizumab, this patient's health markedly improved, as seen by a reduction in subretinal fluid. Conclusion:  The intravitreal injection of ranibizumab has demonstrated efficacy in the treatment of age-related macular degeneration in middle-aged adults.

Full Text:

PDF

References


1. Takayanagi Y, Ashida M, Go M, Gunji M, Sato I, Kato S, et al. Asso-ciation of familial macular degenera-tion with specific genetic markers: a case report. J Med Case Reports. 2015 Dec;9(1):269.

2. Ruan Y, Jiang S, Gericke A. Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Ves-sels. Int J Mol Sci. 2021 Jan 28;22(3):1296.

3. Ma HH, Liutkevičienė R. Age-Related Macular Degeneration: What Do We Know So Far? Acta Med Litu. 2021;28(1):36–47.

4. Miller JW, D’Anieri LL, Husain D, Miller JB, Vavvas DG. Age-Related Macular Degeneration (AMD): A View to the Future. J Clin Med. 2021 Mar 8;10(5):1124.

5. Francisco SG, Smith KM, Aragonès G, Whitcomb EA, Weinberg J, Wang X, et al. Dietary Patterns, Carbohy-drates, and Age-Related Eye Diseas-es. Nutrients. 2020 Sep 18;12(9):E2862.

6. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Opti-cal coherence tomography angi-ography. Progress in Retinal and Eye Research. 2018 May;64:1–55.

7. Nguyen T, Urrutia-Cabrera D, Liou RH-C, Luu CD, Guymer R, Wong RC-B. New Technologies to Study Functional Genomics of Age-Related Macular Degeneration. Front Cell Dev Biol. 2021 Jan 11;8:604220.

8. Hadziahmetovic M, Malek G. Age-Related Macular Degeneration Re-visited: From Pathology and Cellular Stress to Potential Therapies. Front Cell Dev Biol. 2021 Jan 25;8:612812.

9. Al-Zamil W, Yassin S. Recent de-velopments in age-related macular degeneration: a review. CIA. 2017 Aug;Volume 12:1313–30.

10. Patel P, Sheth V. New and Innova-tive Treatments for Neovascular Age-Related Macular Degeneration (nAMD). JCM. 2021 May 30;10(11):2436.

11. Rahman EZ, Singer MA. Broluci-zumab as treatment of wet age-related maculopathy. Drugs Today. 2020;56(11):699.

12. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treat-ment of Neovascular Age-Related Macular Degeneration. Ophthalmo-logica. 2021;244(2):93–101.

13. Brandl C, Breinlich V, Stark KJ, En-zinger S, Aßenmacher M, Olden M, et al. Features of Age-Related Macu-lar Degeneration in the General Adults and Their Dependency on Age, Sex, and Smoking: Results from the German KORA Study. Thatcher TH, editor. PLoS ONE. 2016 Nov 28;11(11):e0167181.

14. Mathenge W. Age-related macular degeneration. Community Eye Health. 2014;27(87):49–50.

15. Heesterbeek TJ, Lorés‐Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for pro-gression of age‐related macular de-generation. Ophthalmic Physiol Opt. 2020 Mar;40(2):140–70.

16. Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27(87):44.

17. Wallsh JO, Gallemore RP. Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Op-tions. Cells. 2021 May 1;10(5).

18. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, et al. Intravitreal Ranibizumab for Diabet-ic Macular Edema with Prompt ver-sus Deferred Laser Treatment: Three-Year Randomized Trial Re-sults. Ophthalmology. 2012 Nov 1;119(11):2312–8.

19. Cheung N, Wong IY, Wong TY. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications. Diabetes Care. 2014 Apr 1;37(4):900–5.

20. Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clinical Ophthalmology (Auckland, NZ). 2017 Nov 6;11:1957.

21. Stanca HT, Stanca S, Tabacaru B, Boruga M, Balta F. Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti‑VEGF era in Romania. Experimental and Therapeutic Medicine. 2019 Dec 1;18(6):4993–5000.

22. Aziz AA, Khanani AM, London N, Hagen MM, Danzig CJ, Kulkarni AD, et al. Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study. Investigative Ophthalmology & Visual Science. 2021 Jun 21;62(8):451–451.




DOI: https://doi.org/10.18860/jim.v8i1.25838

Refbacks



 

Editorial Office:

Faculty of Medical and Health Sciences,
Universitas Islam Negeri Maulana Malik Ibrahim
Gedung Ibnu Thufail Lt.1, Jln. Locari, Desa Tlekung, Kota Batu
Phone (+62) 85746163772, (+62) 8563588384, Faximile (+62) 341 558933
e-mail: medicaljournal@uin-malang.ac.id

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.